Vanda Pharmaceuticals: An Early Stage Bioscience Consideration

Summary

• FDA-approved molecules (Fanapt and Hetlioz) are generating significant revenues.
• Potential approval for other indications to drive further sales growth.
• Hetlioz is highly likely to gain additional approvals (and to service the substantial markets of jet lag and Smith-Magenis syndrome).

Only July 21, 2017, Vanda Pharmaceuticals (NASDAQ:VNDA), a firm that specializes in the development and commercialization of drugs to serve the unmet needs in psychiatry, received negative opinions from the EMA (re Fanaptum for schizophrenia treatment). The Agency stated that therapeutic benefits are not robust to justify potential risks. In response, the company intends to resubmit its application in the foreseeable future. Despite the negative news, we strongly believe that there is much value in this small cap bioscience firm.

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Spectrum Pharmaceuticals: Will Rolontis Substantially Increase Prospects?

Summary

• Fusilev delivered opportunistic growth for Spectrum but earnings are now dependent on the six approved cancer drugs.
• Despite lackluster sales, approved therapeutics generate meaningful incomes to fund further innovation.
• Developing molecules (poziotinib and Rolontis) are likely to post positive data (and to deliver significant sales).

During the 2009 to 2012 leucovorin shortage, shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) (a firm that focuses on the development and commercialization of drugs to treat blood disorders and cancers) soared from $5 to $17 peak. The company's lead drug, Fusilev, a pure racemic form of leucovorin, is used as a folate analog for methotrexate rescue therapy. It is also indicated in combinations with 5-fluorouracil for the palliative management of advanced metastatic colorectal cancer.

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Big profits/safety in a changing market via high-level intelligence from the Columbia scientist, doctor/market expert

Investing in bioscience stocks can be lucrative if - and only if - an investor has an expert edge. Chief Medical Analyst, Dr. Tran is a physician with years of experience in the bioscience field. He has a highly accurate record of clinical data forecasting that is nearly prescient. Leveraging on his strengths, Integrated BioSci Investing ("IBI") seeks to demystify medical jargon and to break down scientific complexities in a way that's easy for the layperson to understand. And, our mission is to translate high-level intelligence into big profits for clients (who we view as business partners).

Extremely well researched, communicated in an easy-to-grasp manner. High potential for capital appreciation ...

At IBI, we have much success in finding stocks that have delivered multiple folds profits. You can review our portfolio in this quarterly assessment. Some of our notable performers are listed below.

Exclusive insight has been proven correct …

Nektar Therapeutics gained +307%.

Spectrum Pharmaceuticals returned +169%. (It also appreciated over 36% in one day, following a positive catalyst forecasting after an MP exclusive article was published).

Atara Biotherapeutics delivered +166%

Crispr Therapeutics gained +113%

Kite Pharma (acquired by Gilead Sciences) profited +82%.

Juno Therapeutics (acquired by Celgene Corporation) procured +45%.

Amicus Therapeutics appreciated +71%.

We maximize our subscribers' chances of discovering multibagger opportunities while diversifying to lower overall risk (including the over-exposure to any particular niche). With our portfolio implementation, we can help you maximize your profits even if the bear market will come.

You'll receive the following exclusive services with subscription:

• Exclusive IBI Long-Term portfolio: At least 30 stocks recommendation (that focuses on areas, including CAR-T, infectious disease, NASH, and immuno-oncology).
• Exclusive Catalysts portfolio: For short-term trading that leverages on binary events analysis and special situations
• Exclusive Alpha Intelligence research: Once-weekly Integrated BioSci best idea as interviews, reports, or research
• Exclusive daily Integrated BioSci analysis: High-level intelligence published in advance of the free articles
• Exclusive Integrated BioSci M&A analysis: Periodic report on potential 2018 M&A
• Exclusive coverage: Weekly portfolio updates and quarterly reviews
• Exclusive consults: Direct communication with the author to answer your questions
• Exclusive chats: Live access to the community of doctors, scientists, fund managers, and everyday investors

Being a part of a supportive community of experts (who are respectful, helpful, and highly successful) can help you beat the market in the long-term. We'll alert you to notable performers so that you won't miss out on robust gains.

Subscribe to our Marketplace research today to lock in the legacy price and save money in the future. Still not convinced? Check out what our partners are saying.

Natural Health Trends: How To Profit From This Aggressive Grower

Summary

• Despite generating less income for Q1 2017 due to a delay in distributors recruiting, business fundamentals remain strong.

• Valuation metrics indicate that the firm is on sales at a significant bargain.

• The prudent course of action is to initiate small purchases while awaiting the upcoming quarter results.

Background

Similar to notable companies operating in the wellness products market, Natural Health Trends (NASDAQ:NHTC) suffered substantial share price depreciation in 2015 due to activist investors’ campaigns and regulatory difficulties. As Chinese authorities probed the firm’s alleged multi-level marketing (“MLM”) practice, the stock tumbled from its $51 peak on Nov. 13, 2015, to $17 by Jan 16 a year ago.

In the triumphant note for shareholders, Natural Health Trends has been vigorously defending against all claims, and thus brought the stock back to $28 as of late. Activism asides, the firm is posting robust yearly earnings growth. And yet, its valuation metrics are highly favorable.

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.